Panacea Index Logo

Command Palette

Search for a command to run...

Survey on treatments for primary headaches in 13 specialized juvenile Headache Centers: The first multicenter Italian study.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
May 1, 2017
Irene Toldo et al. (21 authors)
Journal ArticleMulticenter StudyHuman Study
Study Details

Study Goal

The researchers aimed to evaluate the self-perceived efficacy and tolerability of melatonin and other treatments in children and adolescents with primary headaches.

Results Summary

Melatonin was used by 10% of subjects for both migraine and tension-type headache, with good perceived efficacy and tolerability. The study did not provide detailed statistical analysis or comparative effectiveness data for melatonin.

Population

Children and adolescents (mean age 12 years) diagnosed with primary headaches (migraine or tension-type headache).

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (20)
InterventionDirectionEndpointPopulationDosageImpactClaim #
Acetaminophen
neutral
to treat attacks
patients with primary headaches
by 76% of cases
were commonly used
#1
non-steroidal anti-inflammatory drugs (in particular ibuprofen)
neutral
to treat attacks
patients with primary headaches
by 46% of cases
were commonly used
#2
Triptans
neutral
-
migraineurs
overall by 6%
were used
#3
Triptans
neutral
-
adolescents with migraine
by 13%
were used
#4
Triptans
increase
efficacy
-
-
with better efficacy than acetaminophen and non-steroidal anti-inflammatory drugs
#5
Preventive drugs
neutral
-
migraineurs
by 19%
were used
#6
Preventive drugs
neutral
-
subjects with tension-type headache
by 3%
were used
#7
flunarizine
neutral
-
migraineurs
18%
was the most frequently used drug
#8
antiepileptic drugs
neutral
-
migraineurs
7%
were used
#9
pizotifen
neutral
-
migraineurs
6%
were used
#10
Pizotifen
increase
perceived efficacy and tolerability
-
-
showed the best perceived efficacy and tolerability
#11
Melatonin
neutral
-
subjects
by 10%
were used
#12
nutraceuticals
neutral
-
subjects
by 32%
were used
#13
Melatonin and nutraceuticals
increase
perceived efficacy and tolerability
subjects
-
with good results in terms of perceived efficacy and tolerability
#14
Non-pharmacological preventive treatments (i.e. relaxation techniques, biofeedback, cognitive-behavioral therapy, acupuncture)
neutral
-
cases
only by 10%
were used
#15
Non-pharmacological preventive treatments
neutral
-
migraine
9%
were used
#16
Non-pharmacological preventive treatments
neutral
-
tension-type headache
15%
were used
#17
non-steroidal anti-inflammatory drugs, especially ibuprofen
neutral
for acute attacks of migraine or tension-type headache
-
-
should be preferred to acetaminophen
#18
non-steroidal anti-inflammatory drugs, especially ibuprofen
increase
efficacy and tolerability
-
-
were usually more effective and well tolerated
#19
Triptans
neutral
for treating migraine attack
adolescents
-
could be used more frequently as first or almost second choice
#20
Abstract

AIM: The purpose of this retrospective multicenter study was to evaluate the use and the self-perceived efficacy and tolerability of pharmacological and non-pharmacological treatments in children and adolescents with primary headaches. METHODS: Study of a cohort of children and adolescents diagnosed with primary headache, consecutively referred to 13 juvenile Italian Headache Centers. An ad hoc questionnaire was used for clinical data collection. RESULTS: Among 706 patients with primary headaches included in the study, 637 cases with a single type of headache (migraine 76% - with and without aura in 10% and 67% respectively; tension-type headache 24%) were selected (mean age at clinical interview: 12 years). Acetaminophen and non-steroidal anti-inflammatory drugs (in particular ibuprofen) were commonly used to treat attacks, by 76% and 46% of cases respectively. Triptans were used overall by 6% of migraineurs and by 13% of adolescents with migraine, with better efficacy than acetaminophen and non-steroidal anti-inflammatory drugs. Preventive drugs were used by 19% of migraineurs and by 3% of subjects with tension-type headache. In migraineurs, flunarizine was the most frequently used drug (18%), followed by antiepileptic drugs (7%) and pizotifen (6%), while cyproheptadine, propanolol and amitriptyline were rarely used. Pizotifen showed the best perceived efficacy and tolerability. Melatonin and nutraceuticals were used by 10% and 32% of subjects, respectively, both for migraine and tension-type headache, with good results in terms of perceived efficacy and tolerability. Non-pharmacological preventive treatments (i.e. relaxation techniques, biofeedback, cognitive-behavioral therapy, acupuncture) were used only by 10% of cases (migraine 9%, tension-type headache 15%). DISCUSSION: Non-steroidal anti-inflammatory drugs, especially ibuprofen, should be preferred to acetaminophen for acute attacks of migraine or tension-type headache, because they were usually more effective and well tolerated. Triptans could be used more frequently as first or almost second choice for treating migraine attack in adolescents. Non-pharmacological preventive treatments are recommended by some pediatric guidelines as first-line interventions for primary headaches and their use should be implemented in clinical practice. Prospective multicenter studies based on larger series are warranted to better understand the best treatment strategies for young people with primary headaches.

Medical Subject Headings (MeSH)
AdolescentAnti-Inflammatory Agents, Non-SteroidalAnticonvulsantsBehavior TherapyChildFemaleHumansItalyMaleMigraine DisordersPediatricsPractice Patterns, Physicians'Retrospective StudiesSurveys and QuestionnairesTension-Type Headache
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality65/10
Citation Metrics
Total Citations23
Citations/Year2.9
Relative Citation Ratio1.61
NIH Percentile67.5%
Research Impact Scores
APT Score0.75
Weight Score1.78
Normalized Score0.63
Related Supplements